Search results for "miR"

showing 10 items of 1117 documents

Exosomal miRNA analysis in Non-Small Cell Lung Cancer (NSCLC) patients' plasma through qPCR : a feasible liquid biopsy tool

2016

Abstract: The discovery of alterations in the EGFR and ALK genes, amongst others, in NSCLC has driven the development of targeted-drug therapy using selective tyrosine kinase inhibitors (TKIs). To optimize the use of these TKIs, the discovery of new biomarkers for early detection and disease progression is mandatory. These plasma-isolated exosomes can be used as a non-invasive and repeatable way for the detection and followup of these biomarkers. One ml of plasma from 12 NSCLC patients, with different mutations and treatments (and 6 healthy donors as controls), were used as exosome sources. After RNAse treatment, in order to degrade circulating miRNAs, the exosomes were isolated with a comm…

0301 basic medicinePathologyLung NeoplasmsImmunology and Microbiology (all)General Chemical EngineeringBiopsynon-small cell lung cancer (NSCLC)NSCLCExosomes0302 clinical medicineCarcinoma Non-Small-Cell LungChemical Engineering (all)CancerGeneral NeuroscienceMicroRNAReal-time polymerase chain reaction030220 oncology & carcinogenesisBiomarker (medicine)MedicineEndopeptidase KCase-Control StudieEngineering sciences. TechnologyHumanmedicine.medical_specialtyReal-Time Polymerase Chain ReactionExosomeGeneral Biochemistry Genetics and Molecular BiologyRibonucleaseIssue 11103 medical and health sciencesRibonucleasesmicroRNAmedicineBiomarkers TumorHumansLiquid biopsymiRNANeuroscience (all)Biochemistry Genetics and Molecular Biology (all)Liquid biopsyGeneral Immunology and Microbiologybusiness.industryCancerBiomarkermedicine.diseaseMicrovesiclesExosomeLung NeoplasmMicroRNAs030104 developmental biologyCase-Control StudiesCancer researchReagent Kits DiagnosticbusinessJournal of visualized experiments
researchProduct

MiR-675-5p supports hypoxia induced epithelial to mesenchymal transition in colon cancer cells

2017

// Viviana Costa 1, * , Alessia Lo Dico 2, * , Aroldo Rizzo 3 , Francesca Rajata 3 , Marco Tripodi 4, 5 , Riccardo Alessandro 6, 7, * , Alice Conigliaro 4, * 1 Innovative Technological Platforms for Tissue Engineering, Theranostic and Oncology, Rizzoli Orthopedic Institute, Palermo, Italy 2 Department of Pathophysiology and Transplantation, Universita degli Studi di Milano, Milano, Italy 3 Unita Operativa di Anatomia Patologica, Azienda Ospedaliera Ospedali Riuniti “Villa Sofia-Cervello”, Palermo, Italy 4 Dipartimento di Biotecnologie Cellulari ed Ematologia, Sapienza University of Rome, Rome, Italy 5 National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy 6 Dipartimen…

0301 basic medicinePathologymedicine.medical_specialtymiRNA675Epithelial-Mesenchymal TransitionTranscription GeneticColorectal cancerDown-RegulationMetastasiMetastasis03 medical and health sciences0302 clinical medicineGliomaCell Line TumormedicinemetastasisHumansEpithelial–mesenchymal transitionNeoplasm MetastasisLymph nodeMetastatic colon cancerCRC; EMT; Hypoxia; Metastasis; MiRNA675; Oncologybusiness.industryhypoxiaEMTHypoxia (medical)medicine.diseaseHypoxia-Inducible Factor 1 alpha SubunitCell HypoxiaCRCTransplantationDNA-Binding ProteinsMicroRNAs030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisColonic NeoplasmsCancer researchmedicine.symptombusinessResearch Paper
researchProduct

The β3 -adrenoceptor agonist mirabegron increases human atrial force through β1 -adrenoceptors: an indirect mechanism?

2017

Background and Purpose Mirabegron has been classified as a β3-adrenoceptor agonist approved for overactive bladder syndrome. We investigated possible cardiac effects of mirabegron in the absence or presence of β-adrenoceptor subtype antagonists. In view of its phenylethanolamine structure, we investigated whether mirabegron has indirect sympathomimetic activity by using neuronal uptake blockers. Experimental Approach Right atrial trabeculae, from non-failing hearts, were paced and contractile force measured at 37°C. Single concentrations of mirabegron were added in the absence or presence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX), β3 (L-748,337), β1 (CGP 20712A),…

0301 basic medicinePharmacologyAgonistmedicine.medical_specialtyIBMXContraction (grammar)PhenoxybenzamineChemistrymedicine.drug_classAdrenergicPharmacology03 medical and health scienceschemistry.chemical_compound030104 developmental biologyEndocrinologyInternal medicineDesipraminemedicinePhosphodiesterase inhibitorMirabegronmedicine.drugBritish Journal of Pharmacology
researchProduct

How β3 -adrenoceptor-selective is mirabegron?

2016

0301 basic medicinePharmacologybusiness.industryAdrenergic beta-3 Receptor AgonistsPharmacology03 medical and health sciences030104 developmental biology0302 clinical medicinemedicineβ3 adrenoceptorMirabegronbusiness030217 neurology & neurosurgerymedicine.drugBritish Journal of Pharmacology
researchProduct

MicroRNA as crucial regulators of gene expression in estradiol-treated human endothelial cells.

2018

Background/Aims: Estrogen signalling plays an important role in vascular biology as it modulates vasoactive and metabolic pathways in endothelial cells. Growing evidence has also established microRNA (miRNA) as key regulators of endothelial function. Nonetheless, the role of estrogen regulation on miRNA profile in endothelial cells is poorly understood. In this study, we aimed to determine how estrogen modulates miRNA profile in human endothelial cells and to explore the role of the different estrogen receptors (ERα, ERβ and GPER) in the regulation of miRNA expression by estrogen. Methods: We used miRNA microarrays to determine global miRNA expression in human umbilical vein endothelial cel…

0301 basic medicinePhysiologymedicine.drug_classEndothelial cellsCèl·lulesDown-RegulationEstrogen receptorEstrogen receptorsBiologylcsh:PhysiologyEpigenetic regulationReceptors G-Protein-Coupledlcsh:Biochemistry03 medical and health sciencesDownregulation and upregulationmicroRNAGene expressionHuman Umbilical Vein Endothelial CellsmedicineCluster AnalysisHumanslcsh:QD415-436EpigeneticsCells CulturedOligonucleotide Array Sequence AnalysisPrincipal Component AnalysisReceptors d'hormoneslcsh:QP1-981EstradiolGene Expression ProfilingUp-RegulationCell biologyGene expression profilingMicroRNAsMetabolic pathway030104 developmental biologyReceptors EstrogenEstrogenMiRNA
researchProduct

SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of m…

2018

Background Chronic myelogenous leukemia (CML) is a myeloproliferative disorder caused by expression of the chimeric BCR-ABL tyrosine kinase oncogene, resulting from the t(9;22) chromosomal translocation. Imatinib (gleevec, STI-571) is a selective inhibitor of BCR-ABL activity highly effective in the treatment of CML. However, even though almost all CML patients respond to treatment with imatinib or third generation inhibitors, these drugs are not curative and need to be taken indefinitely or until patients become resistant. Therefore, to get a definitive eradication of leukemic cells, it is necessary to find novel therapeutic combinations, for achieving greater efficacy and fewer side effec…

0301 basic medicineProteomicsCancer ResearchCurcuminCML cellsCellReceptors Cytoplasmic and NuclearKaryopherinsTransfectionlcsh:RC254-282Mass SpectrometrymiR-22/IPO7/HIF-1α axis03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemiR-22/IPO7/HIF-1α axiSettore BIO/13 - Biologia Applicatahemic and lymphatic diseasesCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansCML cells; Curcumin; miR-22/IPO7/HIF-1α axis; SWATH-MS; Oncology; Cancer ResearchOncogeneChemistryResearchCML cellImatinibTransfectionmedicine.diseaseHypoxia-Inducible Factor 1 alpha Subunitlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthMicroRNAs030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchCurcuminSWATH-MSK562 CellsTyrosine kinaseK562 cellsChronic myelogenous leukemiamedicine.drug
researchProduct

Curcumin modulates chronic myelogenous leukemia exosomes composition and affects angiogenic phenotype, via exosomal miR-21

2016

Abstract: Tumor derived exosomes are vesicles which contain proteins and microRNAs that mediate cell-cell communication and are involved in angiogenesis and tumor progression. Curcumin derived from the plant Curcuma longa, shows anticancer effects. Exosomes released by CML cells treated with Curcumin contain a high amount of miR-21 that is shuttled into the endothelial cells in a biologically active form. The treatment of HUVECs with CML Curcu-exosomes reduced RhoB expression and negatively modulated endothelial cells motility. We showed that the addition of CML control exosomes to HUVECs caused an increase in IL8 and VCAM1 levels, but Curcu-exosomes reversed these effects thus attenuating …

0301 basic medicineProteomicsCurcuminProteomeAngiogenesisRHOBNeovascularization PhysiologicAntineoplastic AgentsexosomesExosome03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSettore BIO/13 - Biologia ApplicataCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositiveHuman Umbilical Vein Endothelial CellsMedicineHumansInterleukin 8MARCKSMyristoylated Alanine-Rich C Kinase SubstrateCMLBiologyCells CulturedNeovascularization Pathologicbusiness.industryexosomes curcumin miR-21 CMLMicrovesiclesCell biologyMicroRNAs030104 developmental biologyOncologychemistryGene Expression RegulationSettore CHIM/09 - Farmaceutico Tecnologico Applicativo030220 oncology & carcinogenesisImmunologyCurcuminmiR-21Human medicinebusinessK562 CellsK562 cellsResearch PaperOncotarget
researchProduct

miRNAs in the Era of Personalized Medicine: From Biomarkers to Therapeutics

2021

In recent years, interest in personalized medicine has considerably increased [...]

0301 basic medicineQH301-705.5Computational biologyCatalysisInorganic Chemistry03 medical and health sciences0302 clinical medicineNeoplasmsmicroRNAtherapeuticsHumansMedicineEpigeneticsPrecision MedicinePhysical and Theoretical ChemistryBiology (General)Molecular BiologyQD1-999Spectroscopyepigeneticsbusiness.industryOrganic ChemistryGeneral Medicinepersonalized medicineComputer Science ApplicationsMicroRNAsChemistryEditorial030104 developmental biology030220 oncology & carcinogenesismiRNAsBiomarker (medicine)biomarkerPersonalized medicinebusinessBiomarkersInternational Journal of Molecular Sciences
researchProduct

Regulatory network analysis in estradiol-treated human endothelial cells.

2021

Background/Aims: Estrogen has been reported to have beneficial effects on vascular biology through direct actions on endothelium. Together with transcription factors, miRNAs are the major drivers of gene expression and signaling networks. The objective of this study was to identify a com-prehensive regulatory network (miRNA-transcription factor-downstream genes) that controls the transcriptomic changes observed in endothelial cells exposed to estradiol. Methods: miR-NA/mRNA interactions were assembled using our previous microarray data of human umbilical vein endothelial cells (HUVEC) treated with 17ß- Estradiol (E2) (1 nmol/lL, 24 h). miRNA--mRNA pairings and their associated canonical pat…

0301 basic medicineQH301-705.5FisiologiaBiologyCatalysisArticleInorganic Chemistry03 medical and health sciences0302 clinical medicineGene expressionCadherin bindingHuman Umbilical Vein Endothelial CellsHumansGene Regulatory NetworksRNA MessengerPhysical and Theoretical ChemistryBiology (General)Molecular BiologyTranscription factorQD1-999Spectroscopytranscription factormiRNAEstradiolMicroarray analysis techniquesOrganic ChemistryPromoterEstrogensGeneral Medicineendothelial cellsComputer Science ApplicationsCell biologyDNA binding siteChemistryMicroRNAs030104 developmental biology030220 oncology & carcinogenesisCell adhesion molecule bindingTRANSFACTranscriptome
researchProduct

Hypoxia‐induced non‐coding rnas controlling cell viability in cancer

2021

Hypoxia, a characteristic of the tumour microenvironment, plays a crucial role in cancer progression and therapeutic response. The hypoxia-inducible factors (HIF-1α, HIF-2α, and HIF-3α), are the master regulators in response to low oxygen partial pressure, modulating hypoxic gene expression and signalling transduction pathways. HIFs’ activation is sufficient to change the cell phenotype at multiple levels, by modulating several biological activities from metabolism to the cell cycle and providing the cell with new characteristics that make it more aggressive. In the past few decades, growing numbers of studies have revealed the importance of non-coding RNAs (ncRNAs) as molecular mediators i…

0301 basic medicineRNA UntranslatedCellProliferationReviewlcsh:ChemistryTransduction (genetics)0302 clinical medicineNeoplasmsGene expressionBasic Helix-Loop-Helix Transcription FactorsTumor MicroenvironmentRNA NeoplasmHypoxialcsh:QH301-705.5SpectroscopyCancerGeneral MedicineCell cycleCell HypoxiaComputer Science ApplicationsCell biologyNeoplasm Proteinsmedicine.anatomical_structure030220 oncology & carcinogenesismiRNAscell cyclemedicine.symptomMiRNASignal TransductionCell SurvivallncRNAsBiologyCatalysisInorganic Chemistry03 medical and health sciencesmicroRNAmedicineHumansHIFViability assayPhysical and Theoretical ChemistryMolecular BiologyOrganic ChemistryCancerHypoxia (medical)medicine.diseaseLncRNA030104 developmental biologylcsh:Biology (General)lcsh:QD1-999
researchProduct